TP-0463518 | m-entrepreneurship.com

Product Name :
TP-0463518

Search keywords :
TP0463518

drugId :
null

Target Vo:
Hypoxia-inducible factor 1 alpha

Target Vo Short Name :
HIF1A

Moa_Name:
Hypoxia-inducible factor 1 alpha inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Taisho Pharmaceutical Holdings Co Ltd

Active Company_Name :

Active Indication_Name:

In Active Indication_Name:
Shock, Hemorrhagic

Termination Status :
Phase 2 Clinical

China Termination Status :

Highest Status:
Discontinued

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Myosin Light Chain 2 Antibody
BTK Antibody (YA816)
LC3A/B Antibody: LC3A/B Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 14 kDa, targeting to LC3A/B. It can be used for WB assays with tag free, in the background of Human, Mouse, Rat.

Author: Betaine hydrochloride

Related Posts